Improving HIV prevention and care for people who use drugs
Reinvigorating HIV Prevention and Care for People Who Use Drugs: Accelerating Progress and Sustaining Gains in the Midst of Societal Disruption
This program helps researchers and community groups strengthen HIV prevention (like PrEP) and treatment for people who use drugs, especially during times of social disruption.
Quick facts
| Grant type | P30 center grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11367923 on NIH RePORTER |
What this research studies
This center funds and coordinates research aimed at making HIV prevention and care work better for people who use drugs. It supports studies on how large-scale social changes (for example, pandemics or service disruptions) affect access to PrEP, testing, and treatment, and it partners with community groups to shape the work. The center trains new investigators, supports pilot and observational studies, and works with local clinics and harm-reduction programs to try practical solutions. If I take part, I might be invited to community meetings, surveys, testing, or related prevention and care activities at local sites.
Who could benefit from this research
Good fit: Ideal candidates are people who use drugs—especially people who inject drugs—who live in or near participating sites and who are living with or at risk for HIV.
Not a fit: People who do not use drugs, live far from participating sites, or have no risk of HIV are unlikely to benefit directly from this program.
Why it matters
Potential benefit: Could increase access to PrEP and HIV treatment and help reduce new infections and deaths among people who use drugs.
How similar studies have performed: Community-engaged HIV and harm-reduction programs have improved testing, treatment retention, and PrEP uptake in some areas, but focused, sustained efforts for people who use drugs remain limited.
Where this research is happening
New York, United States
- New York University — New York, United States (Active)
Researchers
- Principal investigator: Hagan, Holly — New York University
- Study coordinator: Hagan, Holly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.